Financial Guidance - Indivior PLC expects total net revenue for 2026 to be in the range of $1.125 billion to $1.195 billion, with SUBLOCADE® net revenue anticipated between $905 million and $945 million [1] - The company aims to grow SUBLOCADE net revenue by 11% at the midpoint of its guidance range, while raising adjusted EBITDA by 35% and adjusted EBITDA margin by 14 percentage points [2] Business Highlights - Indivior PLC was included in the S&P SmallCap 600® index effective December 22, 2025 [3] - The company received shareholder approval to change its domicile from the U.K. to the U.S., with the new U.S. parent company, Indivior Pharmaceuticals, Inc., expected to take effect on January 26, 2026 [3] - Indivior paid off an outstanding obligation of $295 million and concluded a legacy U.S. Department of Justice matter [3] Company Overview - Indivior PLC develops, manufactures, and sells buprenorphine-based prescription drugs for treating opioid dependence, with products including Suboxone Film, Suboxone Tablet, and Subutex Tablet [4] - The company's operations are divided into geographical segments: United States, Rest of World, and United Kingdom [4]

Q3 2025 Performance Highlights - Total net revenue increased by 2% to $314 million compared to $307 million in Q3 2024[11] - SUBLOCADE net revenue increased by 15% to $219 million compared to $191 million in Q3 2024[11] - Adjusted EBITDA increased by 14% to $120 million compared to $105 million in Q3 2024[11] Financial Guidance Update - Total net revenue guidance raised to $1180 million - $1220 million, a 1% increase compared to previous guidance[34] - SUBLOCADE net revenue guidance raised to $825 million - $845 million, a 10% increase compared to previous guidance[34] - Adjusted EBITDA guidance raised to $400 million - $420 million, a 15% increase compared to previous guidance[34] Strategic Initiatives - The company is executing Phase I of the Indivior Action Agenda, focusing on generating momentum[13, 42] - Expect at least $150 million in Non-GAAP operating expense savings in 2026[17, 35] - U S SUBLOCADE YTD net revenue growth of 7% to $561 million compared to $524 million[17]

Group 1 - Indivior PLC will participate in the Stifel 2025 Healthcare Conference on November 13, 2025, with CEO Joe Ciaffoni and CFO Ryan Preblick hosting meetings and a fireside discussion [1] - The fireside discussion will be publicly available via a live webcast [1] - Indivior focuses on developing medicines for opioid use disorder (OUD) and aims to transform OUD into a recognized chronic disease [1] Group 2 - Indivior is set to report its third quarter 2025 financial results on October 30, 2025, at 7:00 a.m. [2] - The company has published results from a clinical trial in JAMA Network Open, supporting rapid SUBLOCADE® induction to improve retention in OUD treatment [3]

Core Viewpoint - Indivior PLC plans to change its domicile from the U.K. to the U.S. by establishing a new parent company, Indivior Pharmaceuticals, Inc. (IPI), to leverage the benefits of its U.S. stock listing [1][2]. Group 1: Redomiciliation Process - The redomiciliation will be executed through a U.K. court-sanctioned scheme of arrangement, requiring shareholder approval [2][3]. - Upon approval, Indivior PLC will become a wholly owned subsidiary of IPI, with IPI's common stock listed on Nasdaq under the symbol INDV [2][3]. - Shareholders will receive one IPI share for each Indivior PLC share held, with Indivior PLC shares cancelled at the time of exchange [2]. Group 2: Timeline and Voting - A formal vote by Indivior PLC shareholders is necessary, requiring a majority in number and 75% in value of shares voted [3]. - Key dates include: - Mid November 2025: Issuance of shareholder circular and notice of extraordinary general meeting (EGM) - Early December 2025: EGM held in London - Late January 2026: Effective date of the scheme and trading of IPI shares on Nasdaq begins [7]. Group 3: Strategic Benefits - The change aims to expand Indivior's presence in U.S. capital markets and increase potential U.S. equity indexation [6]. - It will simplify corporate governance and reduce complexity, positioning Indivior as a U.S.-based treatment innovator [6]. - The move is expected to enhance collaboration with public health leaders on advancing SUBLOCADE® for opioid use disorder [6].